Literature DB >> 24479685

Interferon-γ induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5 in macrophages.

Martin Kuss1, Eleni Adamopoulou, Philipp J Kahle.   

Abstract

The gene encoding leucine-rich repeat kinase 2 (LRRK2) comprises a major risk factor for Parkinson's disease. Recently, it has emerged that LRRK2 plays important roles in the immune system. LRRK2 is induced by interferon-γ (IFN-γ) in monocytes, but the signaling pathway is not known. Here, we show that IFN-γ-mediated induction of LRRK2 was suppressed by pharmacological inhibition and RNA interference of the extracellular signal-regulated kinase 5 (ERK5). This was confirmed by LRRK2 immunostaining, which also revealed that the morphological responses to IFN-γ were suppressed by ERK5 inhibitor treatment. Both human acute monocytic leukemia THP-1 cells and human peripheral blood monocytes stimulated the ERK5-LRRK2 pathway after differentiation into macrophages. Thus, LRRK2 is induced via a novel, ERK5-dependent IFN-γ signal transduction pathway, pointing to new functions of ERK5 and LRRK2 in human macrophages. Leucine-rich repeat kinase 2 (LRRK2) is a major risk factor for the development of Parkinson's disease (PD). However, the role of LRRK2 in the affected neurons remains enigmatic. Recently, LRRK2 has been reported to be strongly expressed in the immune system. Here, we demonstrate that LRRK2 is induced by Interferon gamma via extracellular signal-regulated kinase 5 (ERK5) in macrophages, thus providing new insights in LRRK2 and ERK5 biology.
© 2014 International Society for Neurochemistry.

Entities:  

Keywords:  extracellular signal-regulated kinase; interferon; leucine-rich repeat kinase; macrophages; mitogen-activated protein kinase; signal transduction

Mesh:

Substances:

Year:  2014        PMID: 24479685     DOI: 10.1111/jnc.12668

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  30 in total

1.  Controlled release of cytokines using silk-biomaterials for macrophage polarization.

Authors:  Andrew R D Reeves; Kara L Spiller; Donald O Freytes; Gordana Vunjak-Novakovic; David L Kaplan
Journal:  Biomaterials       Date:  2015-09-21       Impact factor: 12.479

Review 2.  The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease.

Authors:  J Schapansky; J D Nardozzi; M J LaVoie
Journal:  Neuroscience       Date:  2014-10-02       Impact factor: 3.590

Review 3.  LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.

Authors:  A Raquel Esteves; Russell H Swerdlow; Sandra M Cardoso
Journal:  Exp Neurol       Date:  2014-06-04       Impact factor: 5.330

4.  Parkinson disease-associated LRRK2 G2019S transgene disrupts marrow myelopoiesis and peripheral Th17 response.

Authors:  Jeongho Park; Jang-Won Lee; Scott C Cooper; Hal E Broxmeyer; Jason R Cannon; Chang H Kim
Journal:  J Leukoc Biol       Date:  2017-07-27       Impact factor: 4.962

5.  G2019S LRRK2 Mutation Enhances MPP+-Induced Inflammation of Human Induced Pluripotent Stem Cells-Differentiated Dopaminergic Neurons.

Authors:  Ying Chen; Qing Yin; Xiao-Yu Cheng; Jin-Ru Zhang; Hong Jin; Kai Li; Cheng-Jie Mao; Fen Wang; Hong-Zhe Bei; Chun-Feng Liu
Journal:  Front Neurosci       Date:  2022-07-06       Impact factor: 5.152

6.  LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.

Authors:  Evan H Howlett; Nicholas Jensen; Frances Belmonte; Faria Zafar; Xiaoping Hu; Jillian Kluss; Birgitt Schüle; Brett A Kaufman; J T Greenamyre; Laurie H Sanders
Journal:  Hum Mol Genet       Date:  2017-11-15       Impact factor: 6.150

7.  LRRK2: dropping (kinase) inhibitions and seeking an (immune) response.

Authors:  Adamantios Mamais; Mark R Cookson
Journal:  J Neurochem       Date:  2014-03-24       Impact factor: 5.372

Review 8.  Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation.

Authors:  Elizabeth M Kline; Madelyn C Houser; Mary K Herrick; Philip Seibler; Christine Klein; Andrew West; Malú G Tansey
Journal:  Mov Disord       Date:  2020-12-14       Impact factor: 10.338

9.  Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo.

Authors:  Elena Kozina; Shankar Sadasivan; Yun Jiao; Yuchen Dou; Zhijun Ma; Haiyan Tan; Kiran Kodali; Timothy Shaw; Junmin Peng; Richard J Smeyne
Journal:  Brain       Date:  2018-06-01       Impact factor: 15.255

10.  A LRRK2 GTP Binding Inhibitor, 68, Reduces LPS-Induced Signaling Events and TNF-α Release in Human Lymphoblasts.

Authors:  Tianxia Li; Bo Ning; Lingbo Kong; Bingling Dai; Xiaofei He; Joseph M Thomas; Akira Sawa; Christopher A Ross; Wanli W Smith
Journal:  Cells       Date:  2021-02-23       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.